Krystal Biotech (KRYS) said Monday its Vyjuvek treatment for dystrophic epidermolysis bullosa received marketing authorization from the European Commission.

The decision allows the marketing of the treatment in all EU member states, as well as Iceland, Norway and Liechtenstein, with availability subject to multiple factors, the company said.

Krystal said it is planning for the treatment's first European launch in Germany in mid-2025.

Shares were up 2% in early trading.